protectin-d1 and hydroxide-ion

protectin-d1 has been researched along with hydroxide-ion* in 1 studies

Other Studies

1 other study(ies) available for protectin-d1 and hydroxide-ion

Article	Year
Full characterization of PDX, a neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregation. FEBS letters, 2009, Nov-03, Volume: 583, Issue:21 Our study aimed to establish the complete structure of the main dihydroxy conjugated triene issued from the lipoxygenation (soybean enzyme) of docosahexaenoic acid, named PDX, an isomer of protectin/neuroprotectin D1 (PD1/NPD1) described by Bazan and Serhan. NMR approaches and other chemical characterization (e.g. GC-MS, HPLC and LC-MS/MS) indicated that PDX is 10(S),17(S)-dihydroxy-docosahexa-4Z,7Z,11E,13Z,15E,19Z-enoic acid. The use of (18)O(2) and mass spectrometry showed that PDX is a double lipoxygenation product. Its structure differs from PD1, with E,Z,E geometry (PDX) instead of E,E,Z (PD1) and S configuration at carbon 10 instead of R. PDX inhibits human blood platelet aggregation at sub-micromolar concentrations. Topics: Arachidonate 15-Lipoxygenase; Carbon; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Gas Chromatography-Mass Spectrometry; Glycine max; Humans; Hydroxides; Magnetic Resonance Spectroscopy; Platelet Aggregation; Stereoisomerism	2009

Article

Year

Full characterization of PDX, a neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregation.

FEBS letters, 2009, Nov-03, Volume: 583, Issue:21

Our study aimed to establish the complete structure of the main dihydroxy conjugated triene issued from the lipoxygenation (soybean enzyme) of docosahexaenoic acid, named PDX, an isomer of protectin/neuroprotectin D1 (PD1/NPD1) described by Bazan and Serhan. NMR approaches and other chemical characterization (e.g. GC-MS, HPLC and LC-MS/MS) indicated that PDX is 10(S),17(S)-dihydroxy-docosahexa-4Z,7Z,11E,13Z,15E,19Z-enoic acid. The use of (18)O(2) and mass spectrometry showed that PDX is a double lipoxygenation product. Its structure differs from PD1, with E,Z,E geometry (PDX) instead of E,E,Z (PD1) and S configuration at carbon 10 instead of R. PDX inhibits human blood platelet aggregation at sub-micromolar concentrations.

Topics: Arachidonate 15-Lipoxygenase; Carbon; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Gas Chromatography-Mass Spectrometry; Glycine max; Humans; Hydroxides; Magnetic Resonance Spectroscopy; Platelet Aggregation; Stereoisomerism

2009